Ratings by Morgan Stanley (Terence Flynn)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/5/2026 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 5/15/2026 | Alumis Inc | ALMS | Maintain | Overweight (N/A) |
|
Details | ||
| 5/13/2026 | Legend Biotech Corp. | LEGN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/13/2026 | Biohaven Pharma | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/11/2026 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 5/11/2026 | Arcus Biosciences | RCUS | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/8/2026 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2026 | United Therapeutics Corp. | UTHR | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/7/2026 | Royalty Pharma | RPRX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/5/2026 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/4/2026 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/1/2026 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 4/30/2026 | Biogen | BIIB | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/28/2026 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/27/2026 | Intellia Therapeutics | NTLA | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/21/2026 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 4/10/2026 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/10/2026 | United Therapeutics Corp. | UTHR | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/10/2026 | Royalty Pharma | RPRX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/10/2026 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/10/2026 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 4/10/2026 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 4/10/2026 | BioNTech | BNTX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/10/2026 | Biogen | BIIB | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/30/2026 | Biogen | BIIB | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/30/2026 | United Therapeutics Corp. | UTHR | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/27/2026 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 3/20/2026 | Alumis Inc | ALMS | Maintain | Overweight (N/A) |
|
Details | ||
| 3/19/2026 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 3/17/2026 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/10/2026 | Legend Biotech Corp. | LEGN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/10/2026 | BioNTech | BNTX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/10/2026 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/6/2026 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 3/5/2026 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 2/26/2026 | United Therapeutics Corp. | UTHR | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/23/2026 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 2/17/2026 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/17/2026 | CRISPR Therapeutics | CRSP | Maintain | Underweight (N/A) |
|
Details | ||
| 2/13/2026 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/12/2026 | Royalty Pharma | RPRX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/11/2026 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 2/9/2026 | Biogen | BIIB | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/5/2026 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 1/20/2026 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 1/13/2026 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 1/8/2026 | Nurix | NRIX | Upgrade | Overweight (Equalweight) |
17.43 (18.86) |
8.2% | Details | |
| 1/8/2026 | Nurix | NRIX | Upgrade | Overweight (Equalweight) |
17.43 (17.43) |
0% | Details | |
| 1/8/2026 | Arcus Biosciences | RCUS | Downgrade | Equalweight (Overweight) |
21.69 (28.18) |
29.92% | Details | |
| 1/7/2026 | Alumis Inc | ALMS | Maintain | Overweight (N/A) |
|
Details | ||
| 1/6/2026 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 12/17/2025 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/12/2025 | Structure Therapeutics | GPCR | Maintain | Overweight (N/A) |
|
Details | ||
| 12/12/2025 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/12/2025 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/12/2025 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 12/12/2025 | Biogen | BIIB | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/5/2025 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/3/2025 | Vertex | VRTX | Upgrade | Overweight (Equalweight) |
425.60 (468.42) |
10.06% | Details | |
| 11/24/2025 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 11/17/2025 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/13/2025 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 11/6/2025 | Royalty Pharma | RPRX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/5/2025 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/4/2025 | BioNTech | BNTX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/31/2025 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 10/31/2025 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 10/30/2025 | United Therapeutics Corp. | UTHR | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/30/2025 | United Therapeutics Corp. | UTHR | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/13/2025 | Nurix | NRIX | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/10/2025 | Vertex | VRTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/10/2025 | United Therapeutics Corp. | UTHR | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/10/2025 | Royalty Pharma | RPRX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/10/2025 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/10/2025 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/10/2025 | BioNTech | BNTX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/10/2025 | Biogen | BIIB | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/3/2025 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 8/15/2025 | Alumis Inc | ALMS | Maintain | Overweight (N/A) |
|
Details | ||
| 8/12/2025 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/8/2025 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 8/8/2025 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 8/7/2025 | Royalty Pharma | RPRX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/7/2025 | Arvinas Inc. | ARVN | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/7/2025 | Arcus Biosciences | RCUS | Maintain | Overweight (N/A) |
|
Details | ||
| 8/5/2025 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/5/2025 | Vertex | VRTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/31/2025 | Biogen | BIIB | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/14/2025 | Nurix | NRIX | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/10/2025 | United Therapeutics Corp. | UTHR | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/10/2025 | Royalty Pharma | RPRX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/10/2025 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 7/10/2025 | BioNTech | BNTX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/27/2025 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 6/23/2025 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 6/20/2025 | Vertex | VRTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 6/4/2025 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 6/3/2025 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 5/29/2025 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/22/2025 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 5/16/2025 | Royalty Pharma | RPRX | New Coverage | Overweight (N/A) |
33.12 (55.35) |
67.12% | Details | |
| 5/12/2025 | Structure Therapeutics | GPCR | Maintain | Overweight (N/A) |
|
Details | ||
| 5/9/2025 | Arvinas Inc. | ARVN | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/9/2025 | Arcus Biosciences | RCUS | Maintain | Overweight (N/A) |
|
Details | ||
| 5/6/2025 | Vertex | VRTX | Maintain | (N/A) |
|
Details | ||
| 5/5/2025 | BioNTech | BNTX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/14/2025 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/13/2025 | Arvinas Inc. | ARVN | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/11/2025 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 3/11/2025 | BioNTech | BNTX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/10/2025 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 3/6/2025 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/3/2025 | Arcus Biosciences | RCUS | Maintain | Overweight (N/A) |
|
Details | ||
| 2/27/2025 | United Therapeutics Corp. | UTHR | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/18/2025 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 2/14/2025 | CRISPR Therapeutics | CRSP | Maintain | Underweight (N/A) |
|
Details | ||
| 2/13/2025 | Biogen | BIIB | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/11/2025 | Vertex | VRTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/27/2025 | Intellia Therapeutics | NTLA | Downgrade | Equalweight (Overweight) |
11.29 (15.25) |
35.08% | Details | |
| 1/15/2025 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/10/2025 | Gilead Sciences | GILD | Upgrade | Overweight (Equalweight) |
90.63 (125.05) |
37.98% | Details | |
| 11/15/2024 | Alumis Inc | ALMS | Maintain | Overweight (N/A) |
|
Details | ||
| 11/8/2024 | Intellia Therapeutics | NTLA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/8/2024 | Arcus Biosciences | RCUS | Maintain | Overweight (N/A) |
|
Details | ||
| 11/5/2024 | Vertex | VRTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/31/2024 | Biogen | BIIB | Downgrade | Equalweight (Overweight) |
183.47 (197.19) |
7.48% | Details | |
| 10/30/2024 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/11/2024 | Vertex | VRTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/11/2024 | United Therapeutics Corp. | UTHR | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/11/2024 | Royalty Pharma | RPRX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2024 | Prime Medicine | PRME | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/11/2024 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/11/2024 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2024 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/1/2024 | Vertex | VRTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/24/2024 | BioNTech | BNTX | Upgrade | Overweight (Equalweight) |
112.28 (90.62) |
-19.29% | Details | |
| 9/23/2024 | Structure Therapeutics | GPCR | New Coverage | Overweight (N/A) |
38.75 (45.61) |
17.7% | Details | |
| 8/27/2024 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 8/9/2024 | Royalty Pharma | RPRX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/9/2024 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 8/5/2024 | BioNTech | BNTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/2/2024 | Vertex | VRTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/1/2024 | United Therapeutics Corp. | UTHR | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/31/2024 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/24/2024 | Biohaven Pharmaceutical Holding | BHVN | New Coverage | Overweight (N/A) |
36.45 (14.78) |
-59.45% | Details | |
| 7/23/2024 | Alumis Inc | ALMS | New Coverage | Overweight (N/A) |
12.50 (24.51) |
96.08% | Details | |
| 7/11/2024 | United Therapeutics Corp. | UTHR | Downgrade | Equalweight (Overweight) |
322.65 (544.33) |
68.71% | Details | |
| 7/2/2024 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 5/13/2024 | Royalty Pharma | RPRX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/13/2024 | Intellia Therapeutics | NTLA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/13/2024 | CRISPR Therapeutics | CRSP | Maintain | Underweight (N/A) |
|
Details | ||
| 5/13/2024 | Arcus Biosciences | RCUS | Maintain | Overweight (N/A) |
|
Details | ||
| 5/8/2024 | Arvinas Inc. | ARVN | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/6/2024 | BioNTech | BNTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/6/2024 | Vertex | VRTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/2/2024 | United Therapeutics Corp. | UTHR | Maintain | Overweight (N/A) |
|
Details | ||
| 5/2/2024 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/9/2024 | Royalty Pharma | RPRX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/1/2024 | Arvinas Inc. | ARVN | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/1/2024 | Revance Therapeutic | RVNC | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/26/2024 | CRISPR Therapeutics | CRSP | Maintain | Underweight (N/A) |
|
Details | ||
| 2/26/2024 | C4 Therapeutics | CCCC | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/20/2024 | Royalty Pharma | RPRX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/7/2024 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 1/11/2024 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 11/13/2023 | Intellia Therapeutics | NTLA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/13/2023 | CRISPR Therapeutics | CRSP | Maintain | Underweight (N/A) |
|
Details | ||
| 11/13/2023 | Arvinas Inc. | ARVN | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/13/2023 | Arcus Biosciences | RCUS | Maintain | Overweight (N/A) |
|
Details | ||
| 11/6/2023 | Prime Medicine | PRME | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/6/2023 | C4 Therapeutics | CCCC | Upgrade | Equalweight (Underweight) |
1.40 (4.22) |
201.43% | Details | |
| 11/3/2023 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 11/2/2023 | United Therapeutics Corp. | UTHR | Maintain | Overweight (N/A) |
|
Details | ||
| 11/1/2023 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/17/2023 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/11/2023 | Royalty Pharma | RPRX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2023 | Revance Therapeutic | RVNC | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/11/2023 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 9/5/2023 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 8/11/2023 | Prime Medicine | PRME | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/11/2023 | CRISPR Therapeutics | CRSP | Maintain | Underweight (N/A) |
|
Details | ||
| 8/11/2023 | Arvinas Inc. | ARVN | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/9/2023 | Royalty Pharma | RPRX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/9/2023 | Revance Therapeutic | RVNC | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/9/2023 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 8/7/2023 | Arcus Biosciences | RCUS | Maintain | Overweight (N/A) |
|
Details | ||
| 8/7/2023 | Intellia Therapeutics | NTLA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/3/2023 | United Therapeutics Corp. | UTHR | Maintain | Overweight (N/A) |
|
Details | ||
| 8/2/2023 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/21/2023 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/21/2023 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 7/21/2023 | Eli Lilly | LLY | Maintain | (N/A) |
|
Details | ||
| 7/21/2023 | Pfizer | PFE | Maintain | (N/A) |
|
Details | ||
| 7/11/2023 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 6/26/2023 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 5/15/2023 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 5/12/2023 | CRISPR Therapeutics | CRSP | Maintain | Underweight (N/A) |
|
Details | ||
| 5/12/2023 | C4 Therapeutics | CCCC | Maintain | Underweight (N/A) |
|
Details | ||
| 5/12/2023 | Arvinas Inc. | ARVN | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/10/2023 | Royalty Pharma | RPRX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/8/2023 | Intellia Therapeutics | NTLA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/3/2023 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/28/2023 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 4/10/2023 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/10/2023 | Royalty Pharma | RPRX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/10/2023 | United Therapeutics Corp. | UTHR | Maintain | Overweight (N/A) |
|
Details | ||
| 4/10/2023 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 2/27/2023 | CRISPR Therapeutics | CRSP | Maintain | Underweight (N/A) |
|
Details | ||
| 2/27/2023 | C4 Therapeutics | CCCC | Maintain | Underweight (N/A) |
|
Details | ||
| 2/27/2023 | Arvinas Inc. | ARVN | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/10/2022 | Arvinas Inc. | ARVN | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/3/2022 | Intellia Therapeutics | NTLA | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2022 | Revance Therapeutic | RVNC | New Coverage | Equalweight (N/A) |
28.89 (3.65) |
-87.37% | Details | |
| 10/11/2022 | NephroGenex, Inc. | NIRX | New Coverage | Equalweight (N/A) |
8.26 (8.26) |
0% | Details | |
| 10/11/2022 | CRISPR Therapeutics | CRSP | New Coverage | Underweight (N/A) |
60.82 (51.48) |
-15.36% | Details | |
| 10/11/2022 | C4 Therapeutics | CCCC | New Coverage | Underweight (N/A) |
7.73 (4.22) |
-45.41% | Details | |
| 10/11/2022 | Intellia Therapeutics | NTLA | New Coverage | Overweight (N/A) |
54.31 (11.29) |
-79.21% | Details | |
| 10/11/2022 | Arcus Biosciences | RCUS | New Coverage | Overweight (N/A) |
26.15 (21.69) |
-17.06% | Details | |
| 10/11/2022 | United Therapeutics Corp. | UTHR | New Coverage | Overweight (N/A) |
205.95 (322.65) |
56.66% | Details | |
| 8/8/2022 | Arvinas Inc. | ARVN | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/6/2022 | Arvinas Inc. | ARVN | New Coverage | Equalweight (N/A) |
73.34 (8.14) |
-88.9% | Details |
